1 2 Background 3 Dried blood spot (DBS) testing for hepatitis C (HCV) was introduced to Scotland in 4
Results 14
In the first two years of usage in Scotland, 1322 individuals were tested by DBS of 15 which 476 were found to have an active HCV infection. Linkage analysis showed that 16 32% had attended a specialist clinic within 12 months of their specimen collection 17 date and 18% had begun anti-viral therapy within 18 months of their specimen 18 collection date. A significantly reduced likelihood of attendance at a specialist clinic 19 was evident amongst younger individuals (<35 years), those of unknown ethnic origin 20 and those not reporting injecting drug use as a risk factor. 21
Conclusion 22
We conclude that DBS testing in non-clinical settings has the potential to increase 23 diagnosis and, with sufficient support, treatment of HCV infection among PWID. 24 25 2 Background 26 27 In Scotland, 0.8% of the population aged 15-59 years had been diagnosed with 28 hepatitis C virus (HCV) antibodies by the end of 2012 [1] . The majority of these 29 infections occur in individuals with a history of injecting drug use [2] and recent 30 estimates suggest that around half of people infected with HCV remain undiagnosed 31 [1] . To tackle the epidemic of HCV in Scotland, the Hepatitis C Action Plan for 32
Scotland was launched in September 2006 [3] . In its initial Phase (September 2006 -33 March 2008) the Action Plan identified poor venous access amongst people who 34 inject drugs (PWID), along with a shortage of trained phlebotomists, and the long 35 interval between testing and return of results, as barriers to testing and diagnosis of 36 HCV in this population [4] . Dried blood spots (DBS), drops of whole blood from a 37 finger prick dried onto filter paper, provide an alternative to whole blood specimens 38 collected by venipuncture and can overcome the majority of barriers to HCV testing 39 outlined above [5, 6, 7, 8] The objective of this study was to determine the proportion of those tested by DBS in 47
Scotland who had been exposed to HCV; of those diagnosed as being currently 48 infected with HCV the proportion attending a specialist clinic and, of those, the 49 proportion who were initiated on anti-viral treatment. Epidemiological information 50 3 collected alongside the DBS specimens is also analysed to identify predictors of 51 exposure, attendance and treatment initiation amongst this population. 52 Not Known (PWID), Non-PWID) and the outcomes: 'HCV antibody positive' (Table  89 1), 'first clinic attendance within 12 months of diagnosis by DBS' (Table 2) and 90 'initiation on antiviral therapy within 18 months of DBS specimen collection' (Table  91 3). For the latter analysis the variable 'Risk Factor' (Current PWID, Past PWID, 92
Study
Non-PWID/Unknown) was also included. For the Risk Factor variable data collected 93 on length of injecting career (including age of first and last injection) was used, where 94 available, to categorise individuals as past PWID and present PWID, with any 95 individual giving a date of last injecting drug use as five or more years prior to the 96 DBS specimen collection date classified as a past PWID. 97 98 All analysis was carried out in R 3.0.1 [8] . In 2009/10 DBS specimens were collected from 1322 individuals in Scotland for 103 HCV screening. Of these individuals 55% (n=728) were seropositive for antibody to 104 HCV, and approximately two-thirds (65.4% (n=476)) had an active HCV infection 105 ( Figure 1 ). Table 1 presents characteristics of the overall study sample, according to 106 HCV antibody prevalence. The majority (70%) were males, although HCV antibody 107 prevalence in both sexes was equal at 55%. The average age of all DBS tested 108 individuals was 36, with 45% of individuals falling into the < 35yrs age category and 109 55% into the ≥ 35yrs category. Antibody prevalence was significantly higher in the 110 older age category compared to the younger; 64% (95% CI: 60 -67%) and 45% (95% 111 CI: 41 -49%) respectively. White was the main ethnicity (82.8%), the remainder 112 being of unknown (16.5%) or non-white (0.7%) ethnicity. Most individuals (89.3%) 113
were tested in a community addiction team or harm reduction setting as opposed to 114 other settings (hospital (3.8%), GP (1.7%), prison (0.6%) or private (4.6%)). 115 116
Odds of HCV antibody 117
Multifactorial logistic regression analysis found age to be related to odds of antibody 118 positivity, with those aged ≥ 35 years significantly more likely (AOR=1.93, 95% 119 CI:1.51 -2.47) than those aged < 35 years to be antibody positive. The adjusted odds 120 ratio of ethnicity was also positively associated with prevalence. Individuals who 121 were recorded as being of white ethnic origin being more likely (AOR=2.00, 95% CI: 122 1.42 -2.85) to be antibody positive as those of unknown/non-white ethnic origin. 123 124 7 PWID are well known to be at increased risk of infection with hepatitis C, particularly 125 those with longer injecting histories. The majority of individuals (85.6%) tested by 126 DBS reported being/having been a PWID; those who did not report injecting drug use 127 as a risk factor were less likely to be antibody positive (AOR=0.28, 95% CI: 0.17 -128 0.39) than those who had commenced injecting in the previous ten years. There was a 129 marked increase in prevalence between individuals who had injected for 10 years or 130 less (46.8%) and individuals with injecting histories of over 10 years (80.0%). This 131 translated into a 3.6-fold increased odds of HCV exposure for the individuals with 132 injecting histories of over a decade (AOR=3.58, 95% CI: 2.36 -5.45) in the adjusted 133 analysis. Finally, although not significant in the multifactorial analysis, individuals 134 tested in a community addiction clinic/harm reduction setting (n=1180) were more 135 likely (OR=1.84. 95% CI: 1.30 -2.63) to be positive for antibody to HCV as those 136 tested in other settings in the univariate analysis (Table 1) . 137 138 Attendance at Specialist Hepatitis Clinics within 12 months of DBS specimen. 139
Of the 728 individuals known to be antibody positive there were 476 (65.4%) 140 individuals with an active HCV infection as confirmed by RT-PCR. Linkage of these 141 individuals to the Hepatitis C Clinical Database showed that 202 (42.4%) had ever 142 attended a specialist hepatitis clinic, and 31.9% (n=152) within 12 months following 143 collection of their DBS specimen (Figure 1 ). For 7.8% (n=37) of individuals a date of 144 attendance prior to the DBS specimen date was also found. 145 146 Univariate analysis did not show any significant relationship between the likelihood 147 of attendance at a specialist hepatitis clinic within the twelve months following 148 diagnosis by DBS and any of the examined variables. However, multifactorial 149 8 logistic regression found a significant relationship between age, risk factor status and 150 ethnicity and attendance at a specialist clinic within 12 months. Individuals aged 35 151 or older were more likely (AOR=1.49, 95% CI: 1.05-2.13) than those aged <35 years 152 to attend a treatment clinic within 12 months of DBS diagnosis. Individuals who were 153 recorded as being of a white ethnic background were also more likely (AOR=2.85, 154 95% CI: 1.57-5.58) to attend a clinic within 12 months as those of a unknown/non-155 white ethnic background, and there was also a significantly reduced likelihood 156 (AOR=0.32, 95% CI: 0.13 -0.71) of attendance at a clinic within 12 months for 157 individuals with a non-PWID risk factor (Table 2) However, there is growing evidence to show that, given adequate support, good 203 treatment outcomes can be achieved among people who continue to inject drugs 204 [12, 13] . 205
206
Looking within our DBS-tested population, logistic regression analysis showed that 207 attendance at specialist hepatitis clinics within 12 months of the DBS specimen 208 collection date was significantly reduced amongst individuals aged less than 35 years 209 and those of unknown/non-white ethnic origin. The significance of the latter finding 210 is unclear as the majority (>98%) of individuals in this category were of unknown 211 ethnicity. We also found that those in the non-PWID risk factor category are 212 significantly less likely to attend a clinic within 12 months of their DBS collection 213 date, despite being chronically infected with HCV. The basis of this difference is 214 unclear but may reflect the high proportion of PWID in our study and the emphasis of 215 this risk factor amongst healthcare professionals working in DBS testing settings. 216
Awareness of these demographic trends amongst healthcare professionals may enable 217 targeted post-test discussion. This analysis did not find any significant association 218 between the variables examined and the likelihood of treatment initiation which may 219 be due to the small sample size and, additionally, our analysis did not have the scope 220 to include the physical, psychological and social factors involved in the decision to 221 treat individuals, and/or willingness to undergo treatment, which have been found to 222 be significant in other studies [14, 15, 16] . is handled in accordance to local NHS governance regulations. DBS specimens are 268 always collected with informed consent and the patient is under no obligation to 269 supply any further information along with the specimen. Patients are made aware that 270 any epidemiological information they do provide is held as anonymous surveillance 271 data and will be used for auditing, public health monitoring etc. 272
